ArticleScientific reports2026
PMMA/pPFPA membrane with low content of modified TiO
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this work, we addressed the issue of pharmaceutical pollution in water by developing new polymer-based membranes with superior separation and photocatalytic properties. The membranes were prepared via the phase-inversion method using poly(methyl methacrylate) (PMMA) and poly(pentafluorophenyl acrylate) (pPFPA) as the main polymers. To enhance absorption capacity and activate photocatalytic properties, modified TiO₂ nanoparticles (TiO2, mod.) were introduced in low concentration. Two porous membranes were fabricated: M1, consisting of PMMA, pPFPA, and TiO2, mod. nanoparticles; and M2, containing the same components as M1 but additionally supplemented with high molecular weight poly(ethylene glycol) (PEG) and polyvinylpyrrolidone (PVP). The incorporation of high-molecular-weight PEG and PVP reduced void formation in the membrane structure, resulting in a denser morphology with smaller pores. The membrane morphology and surface properties were characterised using scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FTIR), zeta potential measurements, and captive bubble contact angle analysis. The average pore diameter decreased from 0.025 μm to 0.0037 μm (85% reduction), resulting in a more uniform pore-size distribution and enhanced membrane structural stability. The surface hydrophilicity, measured using the captive bubble method, improved from 20° to 15°, corresponding to a 25% decrease in contact angle, indicating enhanced hydrophilicity of the PMMA/pPFPA/TiO2, mod./PEG/PVP membrane. The membrane was tested against a pharmaceutical mixture of metoprolol (MPL), ibuprofen (IBU), and diclofenac (DCF) in dynamic (cross-flow) and static (photocatalysis, sorption) modes. The cross-flow membrane rejection of pharmaceuticals followed the order DCF < IBU < MPL and did not exceed 30%. Independent sorption experiments indicated retention rates of 50–70%, while photocatalytic degradation achieved complete removal (100%) within 2 h. These results clearly separate the contributions of rejection, sorption, and photocatalysis, highlighting the membrane’s potential for practical applications in water treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.